Navamedic ASA: Double Digit Growth in the 3rd Quarter, 2025
Navamedic ASA (OSE: NAVA), a Nordic pharma company, reported revenues of NOK 138.9 million in the third quarter of 2025, representing a 12.9% increase from the same period in 2024.
The company's gross margin improved to 37.5%, compared to 37.1% in Q3 2024. Adjusted EBITDA amounted to NOK 11.3 million, up from NOK 8.6 million in 2024.
The revenue growth was driven by increases in all three business areas, including the Rx business area, which generated NOK 10.6 million in revenues from the dne business.
No additional statements were provided.
Author's summary: Navamedic ASA reports 12.9% revenue growth in Q3 2025.
More News
- Obituaries – Week of Oct. 27, 2025 - The Observer
- Building a stable ‘abode of thought’: Kant’s rules for virtuous thinking
- Hauser headlines Noosa Triathlon as Gentle squeezed out
- Gold breaks records as digitalisation opens the next wave of demand
- Sixers Bell Ringer: Sixers storm back to shock Wizards in OT and remain unbeaten